Securisyn Medical

Securisyn Medical

Growth Stage

Patented interlocking medical devices prevent costly & deadly tube dislodgement

Patented interlocking medical devices prevent costly & deadly tube dislodgement

Overview

Raised this Round: Raised: $112,484

Total Commitments ($USD)

Platform

Republic

Start Date

10/31/2022

Close Date

12/31/2022

Min. Goal
$100,000
Max. Goal
$5,000,000
Min. Investment

$100

Security Type

SAFE

Series

Series A

SEC Filing Type

RegCF    Open SEC Filing

Valuation Cap

$40,000,000

Discount

20%

Year Founded

2011

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B

Margin

Medium

Capital Intensity

High

Location

Littleton, Colorado

Business Type

Growth

Securisyn Medical, with a valuation of $40 million, is raising funds on Republic. The company makes patented interlocking medical devices that prevent tube dislodgement. The flagship product of Securisyn Medical is called SolidAIRity Flex and provides endotracheal tube securement for airway stability for ventilated patients. The device works on Securisyn’s patent-pending Interlock Securement System. The company is led by an experienced team and has an exclusive global manufacturing and distribution partnership with SunMed. Arthur Kanowitz founded Securisyn Medical in January 2011. The current crowdfunding campaign has a minimum target of $100,000 and a maximum target of $5 million. The campaign proceeds will be used to fund the commercial launch and expanded adoption of the SolidAIRity Flex device.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$4,454

$1,188,538

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-1,261,856

$-2,380,266

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$369,852

$730,518

Accounts Receivable

$4,618

$45,618

Total Assets

$851,987

$1,088,727

Short-Term Debt

$1,061,475

$2,330,940

Long-Term Debt

$3,266,577

$978,487

Total Liabilities

$4,328,052

$3,309,427

Financials as of: 10/31/2022
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Analyst Report Analyst Report Methodology Article

Healthcare providers commonly use tape to secure breathing tubes used to keep ventilated patients alive. But tape is so unstable that unplanned extubation (the accidental removal of a breathing tube from an airway) is associated with 33,000 preventable deaths each year in the United States. 

The technology is archaic. In fact, it’s a joke. Somehow, no company has stepped forward to offer a product that can prevent the epidemic of endotracheal tube slippage and unplanned extubation. 

Until now.

The company I’m introducing to you today — Securisyn Medical — has patented a tube stabilization device that solves the life-threatening issues surrounding unplanned extubation and tube slippage.

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Securisyn Medical on Republic 2022
Platform: Republic
Security Type: SAFE
Valuation: $40,000,000

Follow company

Follow Securisyn Medical on Republic 2022

Buy Securisyn Medical's Deal Report

Warning: according to the close date for this deal, Securisyn Medical may no longer be accepting investments.

Securisyn Medical Deal Report

Get KingsCrowd’s comprehensive report on Securisyn Medical including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Securisyn Medical is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise
  • Our deep-dive analyst report reviewing the deal's investment potential and bullish vs. bearish outlook

Buy the Securisyn Medical deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge